Glycoproteins secreted into plasma from T cells infected with human immunodeficiency virus (HIV) latent infection may provide insight into understanding the host response to HIV infection in vivo. Glycoproteomics, which evaluates the level of the glycoproteome, remains a novel approach to study this host response to HIV. In order to identify human glycoproteins secreted from T cells with latent HIV infection, the medium from cultured HIV replicationcompetent T cells was compared with the medium from cultured parental A3.01 cells via solid phase extraction of glycopeptides (SPEG) and high-performance liquid chromatography-Tandem mass spectrometry (HPLC-MS/MS). Using these methods, 59 human glycoproteins were identified as having significantly different abundance levels between the media from these two cell lines. The relevance of these 59 proteins to HIV infection in vivo was assessed in plasma from HIV+ and HIV- subjects. Comparison between T cell and plasma revealed that six glycoproteins (galectin-3-binding protein, L-selectin, neogenin, adenosine deaminase CECR1, ICOS ligand and phospholipid transfer protein) were significantly elevated in the HIV+ T cells and plasma studies. These findings suggest that the response of T cells harboring latent HIV infection contributed, in part, to the glycoprotein changes in HIV+ plasma. These proteins, once validated, could provide insight into host-HIV interaction.
Bibliographical noteFunding Information:
We thank Dr. Xiao-Fang Yu who provided the biosafety level-3 lab at the Johns Hopkins Bloomberg School of Public Health. We gratefully acknowledge the support from the Mass Spectrometry Core Facility at the Johns Hopkins University. We gratefully acknowledge Dr. Stefani N. Thomas and Robert Harlan for proofreading. This research was supported by a National Institutes of Health - National Heart Lung and Blood Institute grant (Program of Excellence in Glycosciences, PEG, P01HL107153) to Dr. Hui Zhang and a National Institutes of Health - National Institute of Allergy and Infectious Diseases grant for the JHU-Guangxi, China Clinical Trials Unit (1U01 AI69482-01) to Dr. Jay Brooks Jackson.
- T cells